InvestorsObserver
×
News Home

Natural Alternativ Down 10.79% To $10.44 After Earnings

Thursday, September 22, 2022 10:54 AM | InvestorsObserver Analysts

Mentioned in this article

Natural Alternativ Down 10.79% To $10.44 After Earnings

Natural Alternatives International, Inc. (NAII) beat out earnings estimates for Q4 2022 this afternoon.

Natural Alternativ's earnings came in at an EPS of $0.52 per share. The firm's earnings are up 11% since reporting $0.47 per share in the same period a year ago. Remember, earnings reported were on an adjusted basis, so they may not be comparable to prior reports and/or analyst estimates.

Revenues were upbeat at $52.5 million. That revenue figure is an increase of 18.33% from the year ago quarter.

The stock is down 10.79% to $10.44 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Natural Alternativ has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 87, putting Natural Alternativ in the top 25% of stocks. The firm set a 52-week low on May 4, 2022 at $8.42 and set a 52-week high on September 22, 2021 at $15.5.

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing, and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment primarily includes royalty income from its license and supply agreements associated with the sale.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App